Solasia Pharma K.K. provided consolidated earnings guidance for the year ending December 31, 2020. For the year, the company expects revenue in the range of JPY 500 million to JPY 2,000 million, operating loss in the range of JPY 2,900 million to JPY 2,000 million, loss in the range of JPY 2,900 million to JPY 2,000 million and basic loss per share of JPY 24.91 to JPY 17.18.